hpv

Human Papilloma Virus type 33 (HPV 33) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 39 (HPV 39) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 57 kDa.

Human Papilloma Virus type 56 (HPV 56) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 59 (HPV 59) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 57 kDa.

Human Papilloma Virus type 18 (HPV 18) Minor capsid Protein L2 (His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 51.6 kDa and the accession number is P06793.

Human Papilloma Virus type 6 (HPV 6) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 55 kDa.

Human Papilloma Virus type 58 (HPV 58) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 16 (HPV 16) Protein E6 (His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 21.2 kDa and the accession number is P03126.

Human Papilloma Virus type 18 (HPV 18) Protein E7 (E. coli, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 16.0 kDa and the accession number is P06788.

Human Papilloma Virus type 16 (HPV 16) Protein E7 (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 15.0 kDa and the accession number is P03129.

Human Papilloma Virus type 11 (HPV 11) Regulatory Protein E2 (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 49.2 kDa and the accession number is P04015.

Human papillomavirus (HPV) 16 infection is a necessary condition for the pathogenesis and development of cervical cancer. The E6 protein is expressed by the HPV16 E6 gene and promotes malignant phenotype transformation, which is an important mechanism for the occurrence and development of cervical cancer.

Human Papilloma Virus type 31 (HPV 31) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 35 (HPV 35) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 16 (HPV 16) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 11 (HPV 11) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 55 kDa.

Human Papilloma Virus type 11 (HPV 11) Protein E4 (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 16.0 kDa and the accession number is P04016.

Human Papilloma Virus type 16 (HPV 16) Minor capsid Protein L2 (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 66.7 kDa and the accession number is P03107.

Human Papilloma Virus type 16 (HPV 16) Protein E4 (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 17.5 kDa and the accession number is P06922.

Human Papilloma Virus type 52 (HPV 52) Protein E7 (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 27.0 kDa and the accession number is P36831.

Human Papilloma Virus type 18 (HPV 18) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 45 (HPV 45) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 52 (HPV 52) L1 Protein-VLP is expressed in Baculovirus insect cells. The predicted molecular weight is 56 kDa.

Human Papilloma Virus type 11 (HPV 11) Protein E7 (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 18.3 kDa and the accession number is P04020.

Human Papilloma Virus type 11 (HPV 11) Regulatory Protein E1 (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 23.1 kDa and the accession number is P04014.

Human Papilloma Virus type 16 (HPV 16) Protein E6 (E. coli, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 23.2 kDa and the accession number is P03126.

Human Papilloma Virus type 18 (HPV 18) Protein E7 (His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 14.0 kDa and the accession number is P06788.

Human Papilloma Virus type 6a (HPV 6a) Protein E4 (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 17.7 kDa and the accession number is Q84295.

Human papillomavirus (HPV) 16 infection is a necessary condition for the pathogenesis and development of cervical cancer. The E6 protein is expressed by the HPV16 E6 gene and promotes malignant phenotype transformation, which is an important mechanism for the occurrence and development of cervical cancer.

HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.

HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.

HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.

The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.